The ability of KRAS inhibition to stimulate antitumor immunity is also supported by conditional genetic mouse models of KRAS-mutant colorectal cancer (28) or PDAC (59) in which suppression of KRAS expression increased influx of T cells. Here, KRAS is linked to colorectal cancer.